{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:33:18Z","timestamp":1782923598326,"version":"3.54.5"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,28]]},"abstract":"<jats:p>Intravenous alteplase thrombolysis is a primary treatment for acute ischemic stroke (AIS), but the optimal dose remains uncertain in patients with stress hyperglycemia. This study aims to compare the changes in neuroinjury biomarker levels, as well as the efficacy and safety, between low-dose (0.6\u2009mg\/kg) and standard-dose (0.9\u2009mg\/kg) intravenous alteplase treatment in patients with AIS and stress hyperglycemia. This study included 150 patients with AIS and stress hyperglycemia, who were divided into a low-dose group (n\u2005=\u200578) and a standard-dose group (n\u2005=\u200572). Differences between the 2 groups were analyzed in terms of neuroinjury biomarkers (neuro-specific enolase, S100\u03b2, glial fibrillary acidic protein, myelin basic protein), neurological recovery (National Institutes of Health Stroke Scale score), clinical outcomes (modified Rankin Scale score), and the incidence of adverse events. Multivariate regression analysis was conducted to evaluate the relationship between the dose and a favorable prognosis (modified Rankin Scale\u2005\u2264\u20052). We found that, within 24 hours post-treatment, the levels of neuroinjury biomarkers (neuro-specific enolase, S100\u03b2, glial fibrillary acidic protein, myelin basic protein) were significantly lower in the low-dose group compared with the standard-dose group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05), and the improvement in National Institutes of Health Stroke Scale scores was more pronounced (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.01). Three months after thrombolysis, the favorable prognosis rate in the low-dose group was 63.5%, higher than the 47.2% in the standard-dose group, with a near-significant difference (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.09). Multivariate regression analysis indicated that low-dose treatment was an independent protective factor for a favorable prognosis (odds ratio\u2005=\u20052.34, 95% confidence interval\u2005=\u20051.29\u20134.23, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.006). There were no significant differences in the incidence of adverse events between the 2 groups, though the proportion of mild bleeding was slightly lower in the low-dose group compared with the standard-dose group. Low-dose intravenous alteplase thrombolysis demonstrates more significant neuroprotective effects in patients with AIS and stress hyperglycemia, promoting neurological recovery and improving long-term prognosis without increasing the risk of adverse events. Low-dose thrombolysis may be a safer and more effective treatment option, but its efficacy and safety require further validation through large-scale, randomized controlled trials.<\/jats:p>","DOI":"10.1097\/md.0000000000041825","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T21:40:40Z","timestamp":1743370840000},"page":"e41825","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Impact of different doses of intravenous alteplase on neuroinjury biomarker levels in patients with acute ischemic stroke and stress hyperglycemia"],"prefix":"10.1097","volume":"104","author":[{"given":"Wei","family":"Yang","sequence":"first","affiliation":[{"name":"Neurology Department, Jianhu County People\u2019s Hospital, Yancheng City, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Chen","sequence":"additional","affiliation":[{"name":"Neurology Department, Jianhu County People\u2019s Hospital, Yancheng City, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7636-1387","authenticated-orcid":false,"given":"Shengmei","family":"Lu","sequence":"additional","affiliation":[{"name":"Neurology Department, Jianhu County People\u2019s Hospital, Yancheng City, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250328","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1001\/jama.2020.26867","article-title":"Diagnosis and management of transient ischemic attack and acute ischemic stroke: a review.","volume":"325","author":"Mendelson","year":"2021","journal-title":"JAMA"},{"key":"R2-20250328","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0140-6736(23)01142-X","article-title":"Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke: individual participant data meta-analysis of six randomised trials.","volume":"402","author":"Majoie","year":"2023","journal-title":"Lancet"},{"key":"R3-20250328","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/cns.13764","article-title":"Stress hyperglycemia is associated with in-hospital mortality in patients with diabetes and acute ischemic stroke.","volume":"28","author":"Mi","year":"2022","journal-title":"CNS Neurosci Ther"},{"key":"R4-20250328","doi-asserted-by":"crossref","first-page":"20962","DOI":"10.1038\/s41598-024-71778-5","article-title":"Association between the stress hyperglycemia ratio and mortality in patients with acute ischemic stroke.","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci Rep"},{"key":"R5-20250328","doi-asserted-by":"crossref","first-page":"1073924","DOI":"10.3389\/fnins.2023.1073924","article-title":"Large vessel occlusion stroke outcomes in diabetic vs. non-diabetic patients with ASH.","volume":"17","author":"Duan","year":"2023","journal-title":"Front Neurosci"},{"key":"R6-20250328","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2147\/JIR.S399021","article-title":"Circulating leukocyte as an inflammatory biomarker: association with fibrinogen and neuronal damage in acute ischemic stroke.","volume":"16","author":"Han","year":"2023","journal-title":"J Inflamm Res"},{"key":"R7-20250328","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12916-024-03517-6","article-title":"Biomarkers of Brain Injury Investigator Study Group. The association between serum S100\u03b2 levels and prognosis in acute stroke patients after intravenous thrombolysis: a multicenter prospective cohort study.","volume":"22","author":"Qu","year":"2024","journal-title":"BMC Med"},{"key":"R8-20250328","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1177\/0271678X231172520","article-title":"Quantification and prospective evaluation of serum NfL and GFAP as blood-derived biomarkers of outcome in acute ischemic stroke patients.","volume":"43","author":"Ferrari","year":"2023","journal-title":"J Cereb Blood Flow Metab"},{"key":"R9-20250328","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1056\/NEJMoa2400314","article-title":"Reteplase versus alteplase for acute ischemic stroke.","volume":"390","author":"Li","year":"2024","journal-title":"N Engl J Med"},{"key":"R10-20250328","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa2118191","article-title":"Endovascular therapy for acute stroke with a large ischemic region.","volume":"386","author":"Yoshimura","year":"2022","journal-title":"N Engl J Med"},{"key":"R11-20250328","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1515510","article-title":"Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke.","volume":"374","author":"Anderson","year":"2016","journal-title":"N Engl J Med"},{"key":"R12-20250328","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1001\/jama.2020.26345","article-title":"Association between dispatch of mobile stroke units and functional outcomes among patients with acute ischemic stroke in Berlin.","volume":"325","author":"Ebinger","year":"2021","journal-title":"JAMA"},{"key":"R13-20250328","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.metabol.2016.11.011","article-title":"Stress hyperglycemia and acute ischemic stroke in-hospital outcome.","volume":"67","author":"Tziomalos","year":"2017","journal-title":"Metabolism"},{"key":"R14-20250328","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4103\/1673-5374.317959","article-title":"Hyperglycemia in acute ischemic stroke: physiopathological and therapeutic complexity.","volume":"17","author":"Ferrari","year":"2022","journal-title":"Neural Regen Res"},{"key":"R15-20250328","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1111\/cns.14163","article-title":"Association between stress hyperglycemia and outcomes in patients with acute ischemic stroke due to large vessel occlusion.","volume":"29","author":"Peng","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"R16-20250328","doi-asserted-by":"crossref","first-page":"1219863","DOI":"10.3389\/fneur.2023.1219863","article-title":"Stress hyperglycemia and risk of adverse outcomes in patients with acute ischemic stroke: a systematic review and dose-response meta-analysis of cohort studies.","volume":"14","author":"Huang","year":"2023","journal-title":"Front Neurol"},{"key":"R17-20250328","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/neurintsurg-2021-018485","article-title":"Hyperglycemic control in acute ischemic stroke patients undergoing endovascular treatment: post hoc analysis of the Stroke Hyperglycemia Insulin Network Effort trial.","volume":"15","author":"Bains","year":"2023","journal-title":"J Neurointerv Surg"},{"key":"R18-20250328","doi-asserted-by":"crossref","first-page":"e209323","DOI":"10.1212\/WNL.0000000000209323","article-title":"Glucose control and risk of symptomatic intracerebral hemorrhage following thrombolysis for acute ischemic stroke: a SHINE trial analysis.","volume":"102","author":"Southerland","year":"2024","journal-title":"Neurology"},{"key":"R19-20250328","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S1474-4422(22)00519-1","article-title":"Thrombolysis for acute ischaemic stroke: current status and future perspectives.","volume":"22","author":"Tsivgoulis","year":"2023","journal-title":"Lancet Neurol"},{"key":"R20-20250328","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1161\/STROKEAHA.120.029749","article-title":"Tenecteplase thrombolysis for acute ischemic stroke.","volume":"51","author":"Warach","year":"2020","journal-title":"Stroke"},{"key":"R21-20250328","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12877-023-03986-z","article-title":"Neuron-specific enolase in hypertension patients with acute ischemic stroke and its value forecasting long-term functional outcomes.","volume":"23","author":"Gao","year":"2023","journal-title":"BMC Geriatr"},{"key":"R22-20250328","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1161\/STROKEAHA.111.614503","article-title":"Early biomarkers of clinical-diffusion mismatch in acute ischemic stroke.","volume":"42","author":"Rodr\u00edguez-Y\u00e1\u00f1ez","year":"2011","journal-title":"Stroke"},{"key":"R23-20250328","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1080\/15548627.2018.1458173","article-title":"Novel insight into circular RNA HECTD1 in astrocyte activation via autophagy by targeting MIR142-TIPARP: implications for cerebral ischemic stroke.","volume":"14","author":"Han","year":"2018","journal-title":"Autophagy"},{"key":"R24-20250328","doi-asserted-by":"crossref","first-page":"104406","DOI":"10.1016\/j.ebiom.2022.104406","article-title":"Kir4.1 channel activation in NG2 glia contributes to remyelination in ischemic stroke.","volume":"87","author":"Hong","year":"2023","journal-title":"EBioMedicine"},{"key":"R25-20250328","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1373\/clinchem.2009.134122","article-title":"Neurobiochemical markers of brain damage in cerebrospinal fluid of acute ischemic stroke patients.","volume":"56","author":"Brouns","year":"2010","journal-title":"Clin Chem"},{"key":"R26-20250328","first-page":"39","article-title":"Deacetylase SIRT2 Inhibition Promotes Microglial M2 Polarization Through Axl\/PI3K\/AKT to alleviate white matter injury after subarachnoid hemorrhage.","volume":"14","author":"Yuan","year":"2024","journal-title":"Transl Stroke Res"},{"key":"R27-20250328","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jocn.2021.10.015","article-title":"Newly-identified blood biomarkers of neurological damage are correlated with infarct volume in patients with acute ischemic stroke.","volume":"94","author":"O\u2019Connell","year":"2021","journal-title":"J Clin Neurosci"},{"key":"R28-20250328","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jama.2020.1511","article-title":"Effect of Intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK Part 2 Randomized Clinical Trial.","volume":"323","author":"Campbell","year":"2020","journal-title":"JAMA"},{"key":"R29-20250328","doi-asserted-by":"crossref","first-page":"e1003910","DOI":"10.1371\/journal.pmed.1003910","article-title":"Association of ischemic stroke onset time with presenting severity, acute progression, and long-term outcome: a cohort study.","volume":"19","author":"Ryu","year":"2022","journal-title":"PLoS Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T21:41:44Z","timestamp":1743370904000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":29,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041825","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}